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Introduction
Deaths from prostate cancer are the consequence of castration resistant (CR) disease that grows despite the low level of circulating androgens in patients treated by androgen deprivation therapy. The androgen growth independent (AI) prostate cancer cells in CR disease have acquired the ability to "reactivate" their endogenous androgen signaling pathway. A tolerable drug that is able to target and block reactivated signaling pathway in AI cells offers an opportunity to increase the lifespan of patients with CR disease and to decrease the death rate from prostate cancer. We proposed that Hedgehog signaling is increased by exposure of prostate cancer cells to androgen-depleted conditions and that this signaling pathway has an important role in in reactivating androgen signaling in androgen deprived prostate cancer cells and in enabling AI growth of prostate cancer cells. Our hypothesis was based upon our preliminary evidence that aspects of Hedgehog (Hh) signaling are awakened in prostate cancer cells switched to an androgen deprived environment and that an inhibitor of Hh signaling (cyclopamine) was able to suppress reactivated androgen signaling in androgendeprived cancer cells. Furthermore, we proposed that drugs that inhibit Hh signaling might be useful in the treatment of advanced/CR prostate cancer. Our experimental Aims were to test whether Hedgehog signaling proteins (Smoothened, Gli1 or Gli2) were involved in regulating androgen-dependent gene expression and androgen-independent growth of prostate cancer cells and to confirm that the suppressive effects of cyclopamine on androgen-dependent gene expression and cancer growth were related to its actions in suppressing Hh signaling in the prostate cancer cell. Other work was designed to test the hypothesis that Hedgehog signaling promotes the local synthesis of androgens in the microenvironment of a prostate tumor. Finally, we sought to test whether the mechanism of cyclopamine action involved effects on β-catenin modification (phosphorylation) and on its ability to interact with the androgen receptor proteins. During the past year, we completed all tasks associated with Aim1 and many of the other tasks associated with the other 3 Aims and this work is described below. While this work represents significant accomplishment, we were greatly affected by Institutional bankruptcy that occurred near the end of the first year but have now found the means to continue this innovative and exciting work at a different institution.
Body (Progress During the First Year) 1. Identification of key roles for Hedgehog signaling proteins (Smoothened, Gli1 and Gli2) in androgen signaling support and AI growth of prostate cancer (Specific Aim 1, Task 1 and 2).
Our proposal was driven by our preliminary evidence that the Hedgehog (Hh) inhibitor drug, cyclopamine, specifically suppressed the expression of androgen-regulated genes in prostate cancer cells and that this effect was linked to suppression of AI growth. The work in Aim 1 was intended to confirm that the action of cyclopamine in this regards was a consequence of its effects on critical Hh signaling gene products that included Smoothened (Smo), Gli1 and Gli2. The tasks in Aim 1 involved manipulating the expression of these key Hh regulators and then measure how this manipulation affected androgen signaling and AI growth in androgen-deprived prostate cancer cells. The manipulations involved increasing the expression of these 3 gene products through transduction of prostate cancer cells with gene expression vectors or decreasing their expression with siRNAs followed by tests on androgen signaling and androgen independent growth of the cancer cells. To this end, we obtained a cDNA expression vector encoding activated Smo as a gift from Dr F. de Sauvage and Genentech, Inc and we separately cloned Gli1 and Gli2 cDNA into tagged expression vectors. Transfection (transient or stable) of each of the vectors into LNCaP cells significantly increased expression of the corresponding mRNAs encoding these genes. While the Gli1/Gli2 vectors likewise induced expression of tagged polypeptides of appropriate molecular weight, the Smo expression vector resulted in the appearance of a super-high molecular weight protein band on Western blots (detected by an anti-Smo antibody) that was strikingly inconsistent with the known molecular weight of human Smo. Likewise, transfection of either Gli1 or Gli2 into androgen deprived LNCaP cells significantly increased the expression the androgen dependent genes and enabled AI growth, but transfection of activated Smo did not. At this time, we postulate that the dysregulated expression of exogenous Smo from the vector resulted in aggregation of this extremely hydrophobic protein in our cancer cells and that the aggregated Smo was dysfunctional. This is supported by our ability to affect androgen signaling through Smo knockdown, described below. However, the evidence that overexpression of active Gli1 or Gli2 was associated with effects on expression of androgen dependent genes and AI growth strongly supports the idea that active Gli proteins interact with the androgen signaling system to increase its activity in a low-androgen condition as we postulated. This effect was also confirmed by a gene knockdown approach. Here, we showed that Smo, Gli1 or Gli2 siRNA was each able to suppress the expression of androgen regulated genes in prostate cancer cells grown in an androgen-free medium. Since the funding decisions for this grant were made relatively late and all tasks associated with Aim 1 were completed prior to project funding, the work was submitted for publication and was rapidly published (1) before project funding was received. For the purposes of this grant, however, we then developed a new Aim 1 that sought to determine the mechanism through which active Gli proteins might promote androgen signaling and AI growth in androgen deprived prostate cancer cells. The tasks in the modified Aim were designed to test whether Gli proteins might directly interact with the AR and act as a co-activator of AR function under low androgen conditions. Indeed, during the first year, we have accumulated significant reproducible data showing that each of the 3 human Gli proteins (Gli1, Gli2 and Gli3) directly interact with AR using a coimmunoprecipitation approach that involved immunoprecipitating one the proteins (Gli or AR) from cell extracts and testing whether the other protein was co-precipitated after Western Blotting (Figure 1 ). The outcome identifies the potential for a direct interaction between each of the individual Gli proteins and the AR protein in prostate cancer cells. Furthermore, by developing a series of partially deleted Gli2 and AR expression vectors, we have mapped the interaction sites of these two proteins (Figure 2 ). At the current time, our data clearly shows that Gli2 interaction with AR requires the presence of a specific region within the C-terminal domain of Gli2 and that the ability of Gli2 to increase AR activity requires the activation domain of Gli2 that also lies within the Gli2 activation domain. With regards to the relative domain on AR needed for interaction with Gli2 protein, we have shown that C-terminal truncated AR still binds effectively to Gli2 and is co-activated by the presence of Gli2. At the current time, our mapping of the AR interaction site is incomplete, but we have already developed a series of AR deletion vectors that will allow us to fine map the Gli2 interaction domain on AR and this should be accomplished within the next two months. With this data on hand, we will submit this work for publication. Please be aware that we have prepared a modified Statement of Work that addresses our essential completion of Aim 1 prior to the funding of the grant and the addition of a new Aim1 involving the work just described that keeps with the theme of the project. Finally, we have published an article citing the support of this grant in which we showed that the Gli-specific inhibitor drug, GANT-61, also suppresses expression of androgen dependent genes under low androgen conditions (2) and this work further substantiates that the Gli proteins, that lie at the end point of the Hh signaling pathway, are involved in the AR reactivation that is associated with long-term androgen deprivation of prostate cancer in conjunction with Hh signaling. ELISA-based assay (4) . Use of these alternative cells provides an additional benefit in that they are highly responsive to Hh agonists whereas prostate tumor cells are not (5) . This allowed us to test whether stimulation of the cells with Hh agonist could induce T biosynthesis from prostate cells. First we conducted a comparative microarray-(CHIP ) based gene profiling done using commercially-obtained primary human prostate stromal cells treated or untreated with the Hh chemical agonist, SAG. The outcome of this profiling effort showed a striking and specific upregulation by the Hh agonist of most of the genes involved in cholesterol biosynthetic pathway along with other select genes involved in androgen biosynthesis and metabolism from cholesterol in these cells ( Figure 3 ). Following up on this observation, we have now shown that treatment with the Hh agonist essentially doubles T production from the adrenal precursor steroid, DHEA (Figure 4 ). Finally, we have found that transduction of the prostate stromal cells with active Gli2 expression vector also increased T output from DHEA and that siRNA against Gli2 blocks the ability of SAG to increase T output from DHEA ( Figure 5 ). Thus, we have obtained evidence both at the gene level and at the steroid production level that active Hh signaling is involved in the production of endogenous androgens from prostate cells. We believe that this modified effort, while proving the point that we sought to establish in our original, unmodified Aim 3, also takes us in a very novel and interesting direction by establishing that paracrine Hh signaling, mediated by upregulation of Hh ligand production from prostate tumor cells following androgen deprivation, can stimulate tumor microenvironmental T production from tumor support cells. While this work was a transient deviation from our original Aim 3 due to the inability of our core facility to sensitively measure androgen production from prostate cancer cells, we will return to this effort and the tasks described in the original SOW with a move to a new Institution (The Prostate Centre at VGH, Vancouver, BC, Canada) with suitable and tested facilities and instrumentation for HPLC/MS measurement of T and DHT output from prostate cancer cells (6) that were described in the original SOW. Therefore, we do not intend to modify the SOW for Aims 2 and 3 but will complete these tasks in our new Institution. HMGCR  DHCR24  ACAT  SCD  IDI1  MVD  INSIG1  FASN  LDLR  LSS  SC4MOL FDPS  SREBF2  SREBF1 17HSDB7 Acetate
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Further Analysis of the Role of β-catenin in Hh-mediated AR activation in androgen-deprived prostate cancer (Aim 4, task 1 and 2).
In our application for this grant, we provided preliminary evidence (based on a single experiment) that cyclopamine, a Hh-inhibitor drug, appeared to suppress phosphorylation of β-catenin in treated prostate cancer cells and also reduced interaction of β-catenin with AR (assessed by co-immunoprecipitation studies). Since others published evidence that phosphorylated β-catenin might be a factor in hyperactive androgen signaling in androgen deprived prostate cancer cells (7), we proposed further experiments to confirm an action of cyclopamine on β-catenin phosphorylation and association with AR. Unfortunately, our experimental efforts in this regards were inconsistent. While we were able to repeat these findings in one additional experiment, in three other attempts, we failed to find reduced interaction of β-catenin with AR after cyclopamine treatment of LNCaP cells. Furthermore, an additional experiment failed to find any suppression of β-catenin phosphorylation upon treatment of LNCaP prostate cancer cells with cyclopamine. The inconsistencies in the outcomes of the multiply repeated experiments, even though they were done with great care and attention to reproducibility, fail to provide us with confidence that this is a useful pathway for further research and we cannot, at this time, support this mechanism for action of cyclopamine. Since we have found plausible and very reproducible evidence for other mechanisms of support of Hh for AR signaling, we will no longer pursue these experiments on β-catenin. We will, however, continue to pursue our efforts to assess the effects of cyclopamine on Fer kinase (Aim 4, tasks 3, 4 and 5) since there is a reasonable body of literature that suggests that Fer kinase is important to prostate cancer progression Chart identifies genes involved in cholesterol (red in top box) or androgen (red boxes, below) that were significantly upregulated (p < 0.05) by treatment of primary human prostate stromal cells with 100 micromolar SAG, a Hedgehog agonist. Assessment was made in a comparative microarray gene expression profiling analysis that compared gene expression in vehicle-treated prostate stromal cells with SAG-treated prostate stromal cells. Profiling was done using the Affymetrix Human ST1.0 Gene Chip and data (results of 2 independent assessments of RNAs in each condition) and data was analyzed using the GeneSpring v.10 soft ware analysis program.
through an unknown mechanism and because of the known interaction of Fer with the microtubule network that is affected by Hh activity or Smoothened inhibition (by cyclopamine or other drugs) in the continuation years.
Complications Faced by Institutional (Ordway Research Institute) Financial Problems and Bankruptcy and
Plans for the Future In December of 2010, the PI (R Buttyan) and the other faculty of Ordway Research Institute (ORI) was informed that the Institute was facing severe financial problems and that our ability to order scientific supplies was thereafter greatly restricted as the Institute was unable to pay any bills incurred without a financial rescue plan. The Institutional Director and the Chief Financial Officer described a feasible plan to accomplish this. However, for the next 3 months, we were forced to only order supplies from alternate companies that were not owed money by ORI so this allowed us to continue our work for that time. Unfortunately, the Institutional plans for solvency were not successful and, on April 28 th of this year, ORI declared bankruptcy. The PI and all other staff associated with this project received a notice of employment termination on that day as were the PIs and staff from most other Divisions of the Institute. We notified the Project Manager of this event and further funding to the Institute was terminated. We feel this discussion is an important part of our progress report because our significant progress, despite the many difficulties presented by these actions, shows that we have the capability to carry out the project in a productive manner and that we have already addressed many of the tasks in our Aims despite these difficulties. The PI is happy to report that he accepted a position as a Senior Scientist at The Prostate Centre of the University of British Columbia and the Vancouver General Hospital in Vancouver, Canada and officially started in this position as of August 1 of 2011. The Prostate Centre is a remarkable UBC Center of Excellence for the study of prostate cancer that encompasses over 15 Principal Investigators, each studying different aspects of prostate cancer with the purpose of integrating research findings into new and more effective clinical treatments for prostate cancer. I am now seeking to continue the project at this site and I am afforded a much better and more well-equipped and prostate-centric working environment than was present at ORI.
The enhanced environment includes a tested HPLC/MS Core system that has already been proven to be able to measure T and DHT production from cultured prostate cancer cells and this will allow us to complete all the tasks under Aim 3. Likewise, the advanced facilities and highly interactive environment will facilitate completion of the rest of the tasks as are now described in the modified SOW.
Key Research Accomplishments
 Created tagged Gli1 and Gli2 expression vectors and showed that they make appropriate proteins when transfected into prostate cancer or other cells (Task 1)  Created stably transduced Smoothened, Gli1 and Gli2 LNCaP cell lines (and control vector transduced) that were used to show that these proteins (Gli1 and Gli2) affect androgen signaling in androgen deprived prostate cancer cells and allow androgen-independent growth (Task 1)  Created a series of partially deleted Gli2 expression vectors that enable mapping of the Androgen Receptor (AR) binding site (New Task 1)  Created a series of partially deleted AR cDNAs that have been used in mapping the Gli2 binding site.  Used co-immunoprecipitation technique to Map specific interaction domains within the Gli2 protein and the AR proteins that may allow the design of small molecular weight inhibitors that might block this interaction (New Task 1)  Successfully used a chromatin immunoprecipitation assay to show that Gli2 protein associates with the androgen response elements on genes that are regulated by androgens (Task 1)  Identified suitable Smoothened, Gli1 and Gli2 siRNAs that knockdown expression of these genes in prostate cancer cells and showed that these siRNAs reduce reactivated androgen signaling in androgen deprived prostate cancer cells (Task 1)  Showed that Gli-blocking drugs suppress reactivated androgen signaling in androgen deprived prostate cancer cells as well as the Smoothened-blocking agent, cyclopamine (Task 1)  Conducted a comparative microarray profiling assay to identify genes affected by cyclopamine treatment of androgen deprived prostate cancer cells (Task 2)
 Successfully measured testosterone levels in conditioned medium of androgen-deprived prostate cancer cells using an ELISA assay and showed that the activation of Hedgehog signaling in prostate cells induces expression of genes associated with steroid and androgen biosynthesis and increases production of androgen from an adrenal precursor steroid (Task 3)  Was unable to confirm the hypothesis that cyclopamine affects the phosphorylation of β-Catenin or its association with androgen receptor protein in cyclopamine-treated prostate cancer cells (Task 4) 
Conclusions
The work accomplished during the first year strongly supports the hypothesis that Hedgehog signaling induced by androgen deprivation can support reactivated androgen signaling in prostate cancer cells leading to increased propensity for androgen independent growth of these cells. Our data also supports the clinical testing of Hedgehog/Gli inhibitory drugs for treatments of prostate cancer patients with advanced disease, in conjunction with androgen deprivation therapy. Conclusions: Collectively, our results indicate that Hh/Gli signaling supports androgen signaling and AI growth in prostate cancer cells in a low androgen environment. The finding that Gli2 co-immunoprecipitates with AR protein suggests that an interaction between these proteins might be the basis for Hedgehog/Gli support of androgen signaling under this condition.
Background
When detected in the advanced stage, prostate cancer patients are treated with hormone therapies that reduce systemic androgen levels [1] [2] [3] . This action palliates the symptoms of metastases, induces regression of metastatic lesions and slows prostate tumor growth [4] . Over time, however, the cancer can recur in a castration resistant form (CRPC) that continues to grow despite the ability of hormone therapy to maintain systemic androgens at castrate levels and deaths from prostate cancer are inevitably associated with complications from this form of disease [5] . Progression of prostate cancer to CRPC appears to involve a reactivation of androgen signaling in the cancer cells [6] [7] [8] and a variety of mechanisms may account for residual androgen signaling in a low androgen environment. These include expression of variant forms of androgen receptor (AR) that are transcriptionally active without ligand [9, 10] , acquisition of an ability to endogenously synthesize androgens by the tumor cells themselves [11, 12] or activation of aberrant AR transcriptional activity through cross-talk with alternate signaling pathways [6, 13] . While all of these mechanisms are of interest from a scientific viewpoint, the ones that are readily targetable by drugs are the most clinically imperative as they offer an opportunity to test novel therapies to treat a disease that will kill almost 28,000 men in the United States this year. Recent reports that Abiraterone, an inhibitor of androgen biosynthesis, has clinical effects against castration resistant prostate cancer, reflects a potential treatment advance that might target tumor cell androgen biosynthesis [14] . Here we describe findings that suggest that inhibitors of the Hedgehog/Gli signaling pathway, currently in clinical testing for a variety of cancers, might also have a role for the treatment of castration resistant prostate cancer due to an ability to suppress reactivated androgen signaling in tumor cells.
Hedgehog (Hh) is best known for its role in tissue patterning and morphogenesis during embryonic development [15] [16] [17] [18] . In the developmental situation, Hh is a ligand-driven process in which a ligand (referred to as a Hedgehog) engages the Patched 1 (Ptch) receptor on the cell surface and this relieves repression of Smoothened (Smo), a member of the extended G protein coupled receptor family [18] . Smo, when activated, then acts downstream to alter the processing and intracellular localization of Gli transcription factors and to increase Gli-mediated transcriptional activity. The plant-derived alkaloid, cyclopamine, is a prototype for a drug that antagonizes the Hh signaling process [19] . Cyclopamine antagonizes Smo activation and this action explains the teratogenic effects of this drug when it is ingested during pregnancy [20, 21] .
Aside from its role in development, Hh signaling also supports stem cells in adult tissues [22] [23] [24] . However, chronically hyperactive Hh/Gli signaling in adult tissues can be oncogenic, especially for the skin or brain [25, 26] . Basal cell carcinoma of the skin and medulloblastoma are models for human Hh-mediated oncogenesis [27] . The aberrant Hh activity in these tumors can result from a loss of the Ptch gene or its function [28, 29] , mutations in Smo [30] or SuFu [31] that activate endogenous Hh signaling or cryptic overexpression of Gli proteins in tumor cells. For prostate cancer, the question as to whether Hh/ Gli signaling plays any role is controversial. Although cyclopamine treatment or Gli knockdown suppresses the in vitro growth of prostate cancer cell lines or xenograft tumor growth in mice [32] [33] [34] , the commonly used prostate cancer cell lines show little, if any, evidence for active canonical Hh signaling activity when they are grown in standard culture conditions [35, 36] . For the androgengrowth dependent LNCaP prostate cancer cells and its variants, C4-2 and C4-2B, however, the situation was found to be changed by chronic exposure of these cells to androgen depleted medium. Androgen deprivation highly upregulated the expression and secretion of Hh ligands and increased endogenous expression of Hh/Gli target genes in these cells [37] . The clinical relevance of this observation is supported by the observation that Hh ligand production was found to be increased in prostate tumors by neoadjuvant hormone treatment [38] . Since cyclopamine suppresses the expression of Hh target genes in androgen-deprived LNCaP cells (37) , this also suggests that active Hh/Gli signaling activity is awakened by growth under androgen deprived conditions. Others have observed that the high basal expression of Hh/Gli target genes in androgen independent (AI) variants of LNCaP was reduced by cyclopamine [39] and, collectively, the outcomes of these studies imply that Hh signaling in LNCaP cells is restricted to the androgen deprived or AI state. The question remains as to whether active Hh signaling has any biological consequences for the androgen deprived or AI prostate cancer cell. Here we show that, by manipulating the activity of canonical Hh signaling in androgen deprived or AI prostate cancer cells, we also affected the expression of androgen regulated genes and the ability of these cells to grow in the absence of androgen. Our results indicate that Hh/Gli signaling activity supports androgen signaling and AI growth in prostate cancer under low/no androgen conditions. Furthermore, we report that Gli2 protein can bind to AR and this interaction might define the point of cross-talk between the two signaling pathways.
Results and Discussion
Previously we reported evidence for conditional activation of canonical Hh signaling in androgen sensitive human prostate cancer cells by culture in an androgen depleted conditions [37] . Here, we used androgen sensitive parental LNCaP cells, other derivatives of LNCaP that are less dependent on androgens for growth (C4-2, LN3, LNCaP-AI) or androgen responsive VCaP cells that are unrelated to LNCaP, to study the effects of Hh signaling manipulation on the expression of androgen regulated genes in these cells. The LNCaP-AI variant cells that we used were independently isolated in our lab following long-term (> 1 year) culture of parental LNCaP cells in androgen depleted medium. These cells downregulate basal expression of Ptch1 when treated with cyclopamine (Additional file 1, Figure S1 ) so they appear to have basal-active Hh signaling activity similar to other AI derivatives of LNCaP that were previously described (39) .
Initially, we tested the effects of the classic Hh inhibitor drug, cyclopamine on androgen regulated gene expression. All experiments were done using a medium that was depleted for androgens (phenol red-free RPMI with charcoal-stripped FBS) that could be re-supplemented with androgen (R1881) to mimic androgen-stimulated conditions. For parental LNCaP cells grown in androgen supplemented medium (+R1881), the presence of cyclopamine had no significant effects on the expression of four model androgen-regulated genes; KLK2, KLK3
[PSA] and PGC (androgen-inducible), or SHH that is repressed by androgen ( Figure 1A) . However, when these cells were switched to androgen depleted medium (-R1881) for 3 days, cyclopamine treatment had a distinct dose-dependent effect that further suppressed expression of KLK2, KLK3 and PGC and further increased expression of SHH ( Figure 1A ). Likewise, cyclopamine significantly downregulated expression of KLK2, KLK3 and PGC in the LNCaP-AI cells that are normally propagated in androgen-free medium, and it upregulated the expression of SHH in these cells ( Figure 1A ). Cyclopamine also suppressed the expression of KLK2 and KLK3 in VCaP, LN3 or C4-2B cells grown in androgen depleted medium for 3 days (Additional file 1, Figure S2 ), so the effects of cyclopamine on androgen regulated genes were not limited to LNCaP or its derivatives. We also tested whether a more water-soluble cyclopamine derivative, KAADcyclopamine, had a similar effect and found that this drug (at 0.5 or 1 μM) was as effective in reducing KLK2/3 and PGC expression in androgen-deprived LNCaP or LNCaP-AI cells as the 5 or 10 μM dose of cyclopamine (Additional file 1, Figure S3 ). Finally, we found that cyclopamine also significantly diminished the expression of a reporter gene (luciferase) from either of two androgen dependent promoters (Probasin [PRB] or PGC) in LNCaP or LNCaP AI cells in androgen depleted medium ( Figure 1B ) in a dose dependent manner. As for endogenous androgen-regulated genes, cyclopamine did not affect the expression of the reporter when cells were cultured in medium supplemented with 10 pM R1881 (data not shown).
Cyclopamine represses Hh signaling through its ability to antagonize Smo activation so we also tested whether Smo expression knockdown (using siRNA) could mimic the effects of cyclopamine with regards to suppression of androgen-inducible gene expression. Figure 2A ). Further assessment of the effects of AR or Smo siRNA on expression of a luciferase reporter from either a Gli-or androgen-responsive promoter showed that AR knockdown selectively reduced expression of the androgen reporter but did not affect expression of the Gli reporter ( Figure  2B ). In contrast, Smo knockdown significantly reduced expression of both the Gli and androgen reporters ( Figure  2B ) in androgen deprived LNCaP cells. In summary, the above data shows that suppression of Hh signaling with a Smo antagonist, cyclopamine, or by reduction of Smo expression itself, suppresses expression of androgen inducible genes and induces expression of androgen repressed genes, but only when these human prostate cancer cells were cultured in a medium lacking androgen. The fact that Smo knockdown reduced expression of androgen regulated genes but did not affect expression of AR mRNA or protein suggests that some aspect of Hh signaling regulates the activity of the AR rather than its expression.
Since cyclopamine suppressed residual/reactivated androgen gene expression in androgen deprived and AI prostate cancer cells, we also sought evidence that this effect had biological consequences relevant to AI growth. First, we tested whether the presence of cyclopamine might prevent the development of AI cells from parental LNCaP cells chronically maintained in androgen depleted medium. LNCaP cells were seeded onto 10 plates at low density and then 5 plates each were switched to androgen depleted medium supplemented with vehicle (EtOH) or with 5 μM cyclopamine. The media were changed every 3 days. Within 2 months, cell numbers in the cyclopaminetreated cultures were significantly reduced compared to vehicle-treated cultures and most surviving cells in the cyclopamine-treated cultures were shrunken with optically dense nuclei that contrasted with the neuroendocrine cell-like appearance of cells in vehicle-treated cultures ( Figure 3A ). By the third month, cyclopaminetreated cultures had less than 1% of the cells of vehicletreated cultures and all remaining cells showed the presence of the optically dense nuclei. No cells remained on cyclopamine-treated plates by 4 months of culture but the cells in the vehicle-treated cultures were increasing in numbers by this time and these cultures gave rise to growing lawns of cells by 6 months that typify AI growth. For overt LNCaP-AI cells, we found that treatment with 5 μM cyclopamine significantly inhibited their growth over a 10 day period ( Figure 3B ) but when cyclopamine treatment was accompanied by supplemental androgen (10 pM R1881), the growth rate of these cells was no different than vehicle treated cells. This indicates that the presence of androgen can overcome the growth-inhibiting effects of cyclopamine on overt AI cells.
Finally, we sought to test whether overexpression of Gli1 or Gli2, transcription factors that lie at the endpoint of the Hh signaling process, might act oppositely to Smo antagonism/inhibition to increase androgen signaling or AI growth when LNCaP cells were grown in androgen free medium. Parental LNCaP cells were transduced with a Gli1-or Gli2-(Gli2ΔN) expressing lentivirus and these cells were compared to control cells transduced with empty virus to determine the effects of Gli overexpression on androgen regulated gene expression and cell growth in androgen depleted medium. The Gli overexpressing variants of LNCaP were also found to express significantly higher levels of KLK2 or KLK3 when compared to control (vector transduced) cells in androgen Table S2 ). (B) LNCaP or LNCaP-AI cells were infected with probasin (PRB) or PGC promoter reporter vectors along with a CMV-GFP reference reporter and were cultured in androgen depleted medium with vehicle (EtOH) or with 5 or 10 μM cyclopamine (Cyc-5 or Cyc-10) for 72 hrs. Cell extracts were assayed for luciferase that was normalized by GFP intensity. Bars represent the means of triplicate experiments ± S.E. (* = P < 0.05 compared to vehicle control; ** = P < 0.05 between 5 and 10 μM cyclopamine treatment groups). depleted medium ( Figure 4A ). Gli1 or Gli2 overexpressing LNCaP cells also expressed significantly higher levels of luciferase reporter from both AR and Gli dependent promoters compared to control cells ( Figure 4B ). Despite higher basal expression of androgen regulated genes, the Gli transduced cells expressed AR protein at equivalent levels to the control cells ( Figure 4C ) so here again, these effects appear to be independent of changes in AR expression. The Gli transduced LNCaP cells also showed significant increased growth in androgen depleted medium compared to the control cells ( Figure 4D ), though Gli2 cells appeared to be more robust than Gli1 in 
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this regard. Regardless of this differential hierarchy, this data shows that Gli function supports androgen regulated gene expression in a low androgen environment as well as AI growth. The evidence that Gli1 or Gli2 overexpression upregulates androgen inducible gene expression and AI growth of androgen deprived LNCaP cells without affecting AR expression suggests that some function of the Gli proteins may support AR transcriptional activity in a low androgen environment. We tested for some potential direct interaction between these Gli and AR proteins in co-immunoprecipitation experiments. Human 293FT cells were transfected with an expression plasmid for fulllength human AR, myc-tagged Gli2 or a combination of these plasmids. Forty-eight hrs later, extracts from the cells were immunoprecipitated with anti-AR or anti-myc antibody and the immunoprecipitates (IPs) were analyzed by Western blot for the presence of AR or myc-tagged Gli2. When the Western blot was probed with anti-AR, we found that AR co-immunoprecipitated with myctagged Gli2 only in extracts from cells co-transfected with both plasmids ( Figure 5 ). Similarly, myc-tagged Gli2 was co-immunoprecipitated in the AR IPs from extracts of cells co-transfected with both plasmids ( Figure 5 ). This apparent interaction between Gli2 and AR in the 293FT cells was not diminished by supplementation with 1 nM R1881.
Here we provided evidence that aspects of the canonical Hh signaling pathway can play a role in supporting residual/reactivated androgen signaling in androgen deprived and AI prostate cancer cells and this finding has important implications with regards to both the mechanistic basis for AI growth in the castration resistant prostate cell and for treatment strategies for CRPC in patients. Smo inactivation by cyclopamine, a cyclopamine variant drug (KAAD-cyclopamine) or reduction in Smo expression by siRNA downregulated androgen inducible genes in androgen deprived and AI prostate cancer cells and these findings suggest that some action of Smo might be important for reactivation of androgen signaling under low androgen conditions. The effects of cyclopamine on androgen regulated genes was common to several types of human prostate cancer cell lines grown under androgen deprived conditions so the effect was not limited to LNCaP cells and derivatives. Cyclopamine also suppressed expression of reporter genes from two different androgen responsive promoters in LNCaP cells in androgen depleted medium and these findings support the idea that Smo activity supports AR-mediated transcriptional activity in the androgen deprived state. Finally, the modulatory effects of cyclopamine on AR regulated gene expression were consistent with the effect of this drug on AI growth. Chronic cyclopamine treatment prevented the development of androgen growth independent cells from parental androgen growth-dependent LNCaP cells and significantly inhibited the growth of an overt AI variant of LNCaP. The cyclopamine-mediated growth suppression was reversed by returning a low level of androgen to the cells, providing further evidence that effects of cyclopamine on development and growth of AI cells are based upon cyclopamines' actions on residual androgen signaling.
Smo action ultimately drives transcription by Gli family proteins so we also tested whether exogenous expression of active Gli had opposite effects of cyclopamine or Smo reduction. Here, our findings that Gli1 or Gli2 overexpression enhanced androgen regulated gene expression in androgen depleted medium and enabled AI growth for androgen growth-dependent cells strongly argues that the active Gli proteins resulting from Hh signaling play the most critical role in Hh-support of residual/reactivated androgen signaling regulation. Although the Gli2 overexpressing LNCaP cells exhibited more robust androgen independent growth than the Gli1 overexpressing cells, it is not possible to rank the effectiveness of the Gli proteins on growth control from this study since the cells may be expressing different amounts of transcriptionally active Gli protein. However, the recent report that Gli2 protein was abundantly expressed in tumor cells With regards to the potential mechanism(s) through which Hh/Gli cross-talks to the androgen signaling pathway, it does not appear to involve changes in the expression of AR mRNA or protein as this was not affected by cyclopamine, Smo knockdown or Gli overexpression. However, the finding that Gli2 and AR proteins co-immunoprecipitate when they were co-expressed in 293T cells does suggest that Gli2 might directly interact with AR to influence the expression of AR target genes in the same manner that other co-activator proteins support AR function [41] . Previously Gli2 was shown capable of binding to CREB or to Zic family transcription factor proteins [42, 43] so this finding extends the potential repertoire of transcription factors capable of interacting with Gli2. It is of further interest that the interaction between AR and Gli2 proteins was not diminished by androgen supplementation. Therefore, the lack of effects of cyclopamine on androgen regulated gene expression in androgen supplemented LNCaP cells might be due to some additional role of other upstream elements of the Hh signaling pathway that are only manifest in androgen depleted cells. Additionally, we must consider the possibility that Hh/Gli signaling is involved in the endogenous production of androgen (intracrine androgen biosynthesis) that is reportedly associated with AI prostate cancer cells [11] , especially since Hh signaling is required for steroidogensis in the testis and for androgen production by other types of cells [44, 45] . This is an aspect that we will test for in future experiments.
Regardless of the mechanism(s) involved, the outcome of this research suggests that Hh/Gli inhibitors offer a specific means to target reactivated androgen signaling in CRPC and to test the idea that inhibition of anomalous androgen signaling in CRPC cells has therapeutic benefit for patients. Although cyclopamine is difficult to use as a therapeutic agent, several pharmaceutical companies are in the process of developing similar drugs that are easier to use in the clinical setting and some of these drugs are through Phase I testing [46] . Therefore, translation of these experimental studies to patients should be able to proceed fairly rapidly. Alternatively, there are noncanonical signaling pathways that increase Gli activity in cancer cells [47] so a clinical focus on Smo antagonists may not be sufficient to deal with all forms of CRPC. Reports of small molecular inhibitors of Hh/Gli signaling that act independently of Smo antagonism [48] , suggests that Hh/Gli signaling provides a rich array of targets for the development of more effective treatments for CRPC.
Conclusions
Modulation of Hh signaling in prostate cancer cells by reduction of Smo expression or activity or by overexpression of active Gli proteins affected androgen signaling and the expression of androgen regulated genes in these cells but only when they were cultured in a low androgen medium. The effects of Hh modulation on androgen regulated gene expression in prostate cancer cells were consistent with the coordinate effects on AI cancer cell development and growth in low androgen medium but these effects were reversed by the presence of androgens. Since we have found that Gli2 protein, at least, interacts with the AR protein, the mechanism through which Hh signaling affects AR-dependent gene expression and AI cell growth may involve a direct interaction of AR with Gli proteins.
Methods
Cells and Culture
Human prostate carcinoma cell lines LNCaP and VCaP were obtained from the ATCC (Manassas, VA). LNCaP variants, LN3 or C4-2B were obtained from Curtis Pettaway, M.D. Anderson Cancer Center (Houston, TX) or ViroMed Laboratories (Minnetonka, MN), respectively. The LNCaP-AI variant was derived from parental LNCaP cells after more than one year growth in androgendepleted medium. Cells were maintained in RPMI-1640 medium with 10% fetal bovine serum (FBS) or switched to phenol red-free RPMI-1640 with 10% charcoalstripped FBS (CS-FBS) for androgen-depleted conditions as previously described (37) . The 293FT cells were obtained from Invitrogen, Inc. (Carlsbad, CA) and were maintained in DMEM with 10% FBS. Synthetic androgen, R1881 (methyltrienolone), was obtained from PerkinElmer Life Sciences (Boston, MA) and was supplemented to androgen-depleted medium at 10 pM where indicated. 
Generation of LNCaP Lines Stably Expressing Gli Transcription Factors
The ViraPower™ Lentiviral Expression System (Invitrogen) was used for generating replication-incompetent lentiviruses expressing recombinant human Gli1 or Gli2ΔN. All procedures were performed according to the manufacturers' protocols with modifications: 1) cDNAs encoding the full-length human Gli1 and the N-terminaltruncated human Gli2 were cloned from the plasmid GLI K12 [49] and pCS2-MT GLI2(ΔN) [50] (Addgene, Cam-bridge, MA) into pLenti6 (Invitrogen); 2) For production of lentivirus in 293FT cells, 3 μg of pLenti6-Gli1, pLenti6-Gli2ΔN or pLenti6-Vec (empty vector control) were mixed with 9 μg of ViraPower Packaging Mix, and 36 μl of Lipofectamine-2000 (Invitrogen). The mixture was applied to 2 × 10 6 293FT cells in medium overnight. Transfection medium was removed and fresh medium was added for another 72 hours. Lentivirus containing medium was collected and filtered and used for infections; 3) LNCaP cells were seeded at 50% confluence overnight in preparation for viral transduction. Virus supernatants were added (diluted 1:5 with medium) and 48 hrs later, blasticidin was added at a concentration of 10 μg/ml for selection. Selection was carried out for 2-3 weeks and ~200 colonies were obtained and pooled as stably-expressing sublines, LNCaP-Vec, LNCaP-Gli1, or LNCaP-Gli2ΔN.
RNA Isolation and Reverse Transcription -Real-Time PCR Assays (RT-qPCR)
RNA was isolated from cells using the RNeasy Mini Kit with RNase-Free DNase digestion (QIAGEN, Valencia, CA). Reverse transcription was carried out using SuperScript ® III First-Strand Synthesis SuperMix for qRT-PCR (Invitrogen) per the supplier's protocol. Real-time PCR was performed on an ABI 7900HT detection system (Applied Biosystems, Foster City, CA) using RT 2 SYBR Green/ROX qPCR Master Mix (SABiosciences, Frederick, MD) according to the manufacturer's protocol. The thermal cycling conditions were as previously described (37) . The message number of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the reference for calculating specific gene messages. The sequences of qPCR primers used are listed in Additional file 2, Table  S1 .
Promoter activity assays
Firefly luciferase reporter vectors under the control of a promoter containing eight repeats of the Gli consensus sequence (pLLRM-GLI-Luc) was generated by sub-cloning the GLI-responsive promoter fragment from pGL3B/ 8XGliBS-lc-luc (JHU-73, ATCC) into a lentiviral luciferase reporter vector, pLLRM. Reporter vectors with rat probasin (PRB) or human Pepsinogen C (PGC) gene promoters and a reference construct expressing GFP under the CMV promoter (pLLCM-GFP) were prepared (Ohouo et al., in preparation) and were used to produce lentiviruses in 293FT cells as described above. Cells were lysed 72 hrs after infection with Passive Lysis Buffer (Promega, Madison, WI) and lysates were analyzed for luciferase activity with the 20/20 n Single Tube Luminometer (Turner Biosystems Inc., Sunnyvale CA) using a Luciferase Assay Kit (Promega). GFP intensity was measured by the BMG FLUOstar Optima plate reader (Imgen Technologies, Alexandria, VA) and used to normalize viral-infection efficiency.
Silencing AR and Smo expression in LNCaP cells by siRNA transfection
The siRNAs specifically targeting human Smo, human AR and control siRNA were purchased from QIAGEN. LNCaP cells were seeded at 70% confluence. siRNAs (40 pM) were mixed with 3 μl of SiLentFect Lipid Reagent for RNAi (Bio-Rad, Hercules, CA) in Opti-MEM I (Invitrogen) for 20 min and this was added to each well in 1.5 ml of medium. Medium was changed 24 hrs after transfection and 72 hrs later, cells were collected for total RNA isolation or lysed in RIPA buffer for Western blot analysis.
Western blot analysis
Cells lysates were assayed for protein and equal amounts of protein were analyzed by Western blot with appropriate antibodies. Each membrane was re-blotted with GAPDH antibody as a control for protein loading. Antibodies were used at the following dilutions: GAPDH at 1:5,000, AR at 1:10,000, and Myc at 1:5,000. Appropriate secondary antibodies conjugated to horseradish peroxidase were used at 1:10,000, and blots were developed by enhanced chemilluminescence reagent (Thermo Fisher Scientific Inc., Rockford, IL). Antibodies to GAPDH or AR receptor (H-280) were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The monoclonal antibody to Myc-tag (4A6) was purchased from Millipore (Billerica, MA).
Cell Proliferation WST-1 Assay
Cells were seeded onto a 96-well plate at a density of 5,000 cells/well in CS-FBS media and were maintained for indicated days (media refreshed every 3 days). At appropriate times, 10 μl WST-1 (Roche, Indianapolis, IN) was added to each well and plates were kept at 37°C for two hrs. Color intensity was read at 450 nm (reference wavelength 650 nm) on the SpectraMax M2 microplate reader (Molecular Devices, Sunnyvale, CA)
Co-immunoprecipitation of AR and Gli2 in 293FT cells
Transfection of 293FT cells (2 × 10 6 cells) with AR or Gli2ΔN plasmids was carried out with Lipofectamine-2000. Cells were lysed in a 1% Triton X-100 lysis buffer with protease inhibitor cocktail (Roche) 48 hrs later. Aliquots of extract containing equal amounts of protein were precipitated at 4°C overnight with 50 μl Dynabeads Protein G (Invitrogen) pre-bound with 5 μg appropriate antibodies. Beads were washed by lysis buffer four times and immunoprecipitated proteins were eluted in 2× SDS sample buffer. The elutant was split into equivalent portions and blotted onto 2 membranes for Western blot analysis. MC conducted the majority of bench experimentation involved in this manuscript and assisted in experimental design and manuscript drafting and editing. MAF conducted some qPCR bench experimentation and reviewed the manuscript for accuracy. EL conducted promoter activity assays and reviewed the manuscript for accuracy. RDC conducted some qPCR bench experimentation and reviewed the manuscript for accuracy. MJT prepared some vectors used in the experimentation and reviewed the manuscript for accuracy. MS prepared some vectors used in the experimentation and reviewed the manuscript for accuracy. FV conducted confirmatory experimentation using the same cells in his laboratory and reviewed the manuscript for accuracy. ST conducted confirmatory experimentation using the same cells in the Vacherot laboratory and reviewed the manuscript for accuracy. AdlT provided funding for the confirmatory experimentation in France and reviewed the manuscript for accuracy. RB provided funding for the experimentation in the US, was responsible for experimental design and data oversight and review and drafted and edited the final manuscript. All authors read and approved the final manuscript. Hedgehog is a ligand-activated signaling pathway that regulates Gli-mediated transcription.
Although most noted for its role as an embryonic morphogen, hyperactive hedgehog also causes human skin and brain malignancies. The Hedgehog-related gene anomalies found in these tumors are rarely found in prostate cancer. Yet surveys of human prostate tumors show concordance of high expression of hedgehog ligands and Gli2 that correlate with the potential for metastasis and therapy-resistant behavior. Likewise, prostate cancer cell lines express hedgehog target genes, and their growth and survival is affected by hedgehog/Gii inhibitors.
To date, the preponderance of data supports the idea that prostate tumors benefit from a paracrine hedgehog microenvironment similar to the developing prostate. Uncertainty remains as to whether hedgehog's influence in prostate cancer also includes aspects of tumor cell autocrine-like signa!!ng. The recent findings that Gli proteins interact with the androgen receptor and affect its transcriptional output have helped to identify a novel pathway through which hedgehog/Gil might affect prostate tumor behavior and raises questions as to whether hedgehog signaling in prostate cancer cells is suitably measured by the expression of Gli target genes alone.
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Hedgehog is a cell ~igna!ing pathway rhar is most noted for its involvement' in cmhryogen~ esis. Increasingly, however, inappropriate hedge~ hog signaling acrivity is viewed as a factor in the development of human malignancy or as a faccor involved in the acquisition of aggressive behaviors of already established rumors. l1ere, we review the putative rolc(s) of hedgehog sign~ aling in prostate cancer. Prostate cancer is a chal~ lcnging disca~c. Aside from the fact that it is the most common malignancy in males [20!] , it poses a considerable dilemma for puhlic health policy with regards to screening and treatment issues. ~or example, even though prostate tumors arc highly invasive, the majority of afHicted men experience prostate cancer as an indolent disease with a relatively slow growth rate[!). Since it is usually diagnosed in men older than 60 years of age, the predominance of indolent prostate cancers raises questions regarding the effective~ ness of prostate cancer screening efforts that are thought to identify large numbers of patient~ for whom the ueatment may be more problematic than the tumor itself [2--t!). These facts highlight the need to understand the etiology that under~ lies the widespread occurrence of this disease and to develop a means of selectively diagnos~ ing those individuals with aggressive form(s).
Second, despite the abundance of indolent dis~ case, owing to its overall high incidence, prostate cancer remains a leading cause of deaths from cancer in males [20!] . This fact underscores the urgent need for better trcatmcms for aggressive disease to reduce mortality. Finally, prostate cancer, in contrast ro other human tumors, is distinguished by a remarkable dependency on androgenic steroids. Prostate cancer only arises in androgcnically intact males, and, when it has spread beyond the confines of the prostate, is commonly treated by hormone therapies that deplete the patient's circulating androgenic stcr~ oid levds [5, 6] [7--10) . Since CRPC cells remain dependent on androgen signaling to grow, this dilemma creates the need to understand the molecular proccss(cs) that enables androgen receptors (ARs) in the CRPC cell to continue to function in the castrate stare. With this understanding, one might be able(() conceive novel therapies to block the aberrant androgen signaling in CRPC cdls and extend the effectiveness of hormone therapies in prostate cancer patients. The focus here on hedgehog signaling in prostate cancer is driven by a growing body ofliterature that addresses various aspects of the signaling pathway in prostate tumors or in prostate cancer cells. Tbis literature is plagued hy contradictions and controversies, yet, despite these problems, many investigators continue to view the outcomes of their studies as evidence for involvement ofhcdgcbog signaling in prostate cancer dcvelopmem or in progression of prostate rumors to aggressive or therapy-resiMant states. In addition, rhe outcomes of some preclinical studies that showed some striking effects of hedgehog-blocking drugs in animal-hased prostate cancer models neatments give strong reason to consider wherher these types of therapies might have value for prostate cancer paticnrs, especially those with advanced or therapy-resistant disease.
Abnormal (hyperactive) hedgehog signaling is already established as being a causative factor for the development of certain types of human skin, brain or cartilage-derived tumors {discussed later). Likewise, published literawre supports the potential for the involvement of particular aspects of the hcdgchog/Gii signaling pathway in other types of solid human tumors\!!-!(,). Here we will first address the nawrc of hedgehog signaling in normal and malignant cells and then describe the literature that suggests rhar hedgehog contributes to human prostate cancer. We will address the controversy as to whether hedgehog acts in prostate cancer exclusively through a paracrine response pathway that mimics hedgehog's involvement in normal prostate development or whether there is any evidence to support a role for a tumor cell-autonomous hedgehog signaling process similar to that found in basal cell carcinoma and medulloblastoma. We will also propose that hedgehog may have an especially important role in promodng progression of pros rare cancer to CRPC, at least partly through Gli support of abnormal androgen signaling in tumors of patients suhsequent w hormone therapy. While the validation of any potential relationship between prostate cancer and hedgehog signaling or hetween the aggressive behavior of the CRPC cell and hedgehog/Gli might provide insights leading to improved diagnosis or prognostication of disease behavior, the availability of several small-molecule inhibitors that target hedgehog/Gii at different parts of the signaling pathway suggests that the most useful hcnefit in exploring this relationship lies in the possibility of using hedgehog-/Gli-blocking drugs to treat patients wirh advanced or hormone rhcrapy-resistam disease who currently have a very poor prognosis.
2
Overview of the hedgehog signaling pathway
Hedgehog is considered to be one of the primal cell signaling pathways that regulates cell fate during embryonic development {along with Wnt and Notch) [!7-!9). Originally discovered in Drosophila, this signaling pathway acquired irs name from the distinctive morphology of certain mucam larvae that were characteristically short and stubby with clustered, spine-like dcntides that occurred as a consequence of disruption of the normal anterior-posterior segmental pattern formation during embryogenesis [20] . This developmental anomaly was then attributed to a mutation in a drosophila gene termed 'hedgehog' that encodes a secreted polypeptide {ligand) that can initiate hedgehog signaling in receptive drosophila cells !21) . We now know rhat some form of hedgehog signaling is evolutionarily conserved throughout metazoans and that hedgehog is an importam tissue morphogen that participates in the establish~ menr of embryonic polarity and tbc early patterning of tissues that sets the stage for acquisition of adult tissue structure and function.
Canonical hedgehog signaling is initiated by peptide ligands that arc still referred to a~· hedgehogs, and it serves, at the end point, to activate transcription from the Gli family oftranscription factors in responsive cells. [22, 23) . Shh is the most well studied and is predominant with regards to its more widespread expression throughout different tissues of the body, although all can similarly engage with receptor to initiate the signaling process. Shh is synthesized as a propolypeptide that is processed by a unique aurocatalytic reaction in which the C-terminal domain cataly:t.cs a cholesterol-dependent intemal cleavage of the pro-form that simultaneously attaches a cholesterol moiety to the cleaved N-tenninal domain [24] . The autocatalysis is not sufficient for secretion of rhe mature ligand; this requires the action of an independent membrane protein referred to as Dispatched [2S] . Cholesterol-modified mature Shh is inherently highly hydrophobic and this can limit its diffusion away from the cells that secretes iL The short-acting nature of the hedgehog signaling process in early development helps to promote the formation of patterns in tissues that arc hascd upon ligand diffusion gradients that restrict ligand access to target cells more distal from the hedgehog-secreting cells.
The signaling process proceeds when the mature ligand engages a receptor on a target cell and, for hedgehog, proteins of the Patched {Ptch) family serve this purpose. Ptch proteins are large, 12-pass membrane proteins, and humans encode two homologs \26), Ptch 1 and Ptch2, with differing affinities for hedgehog ligands and differential expression in various tissues of the body. A diagram of the general intracellular process that accompanies hedgehog signaling is shown in FlGUiu; 1. It should be noted that the brief schema described here is specific for vertebrate-derived cells as evolution from invertebrates was accompanied by modifications that tether the proximal stage of hedgehog signal processing to the subcellular organelle referred to as rhe primary cilia [27, 28] cells with unique o pporrunities ro regulate rhe signaling process, but the linkage also has some imporram implications fo r our understanding of hedgehog acrion in human tumors, as will be discussed later. Likewise, venebrates have a more complex endresponse ro hedgehog signali ng through evolmionary divergence of the fu nction of the inven ebrare Ci rranscription facror that is activated by hedgehog onro th ree different G li proteins (G lil, 2 and 3) in vertebrates [29,301. Since the topic of t his treatise is human prostate cancer, hereafter our d iscussion will focus on the signaling pathway as it is known to function in higher vertebrates (mouse through humans). Ligand engagement of Ptch reli eves repression of the Smoothened (Smo) protein rhat is required for furrher signaling. Smo, a seven-pass rransmembrane protein of the extended G-protein-coupled receptor family, has an active and an inactivate state that appears to be defined both by irs location within rhe cell (i nside or outside of the p rimary cilia) [311 and by other modifications that may include its abi lity to capture oxysterols at an active sire [32,331. Smo activation requires two steps that were operationally defined by cerrain low-molecu lar-weight www.expcn .. revic:ws.eom compounds that disrupt the activation process [34) . The first step involves the movemem of Smo protei ns from the plasma membrane and endoplasmic vesicles into primary ci lium and here unl iganded Ptch acts as a gatekeeper that restricts access of Smo to the primary cil ium. Ptch action in t his regard is m imicked by t he drug, SAN ·l~l. which simi la rly suppresses ci liary accumu lation of Smo, even in the presence of ligand [35, 36) . Once in the primary ci lia, however, Smo activation requires a secondary step that is also regulated by Ptch, and this activation step is operationally defined by inhibition with cyclopam ine or derivatives that allow Smo ciliary accumulation bm prevenr any furrher downstream signaling activities. T he nature of t he secondary Smo activation event remains enigmatic, although it probably involves a conformational shift and/or a change in Smo interaction with other ciliary proteins t hat arc involved in hedgehog signal processing. Regardless of our understanding of this particular cvenr, the presence of active Smo within primary cilia induces a functional cha nge in the organelle that fundamenrally alters the manner in which the two dominam Gli proteins, Gli2 and Gli3, are post-translationally processed.
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As transcription factors with shared function, all Gli proteins have a homologous internal DNA-binding domain that recognizes and binds a cis-regulatory consensus motif on DNA: G-A-C-C-A-C-C-A [37) . The lack of this consensus sequence within or ncar any given gene docs not preclude regulation by Gli since functional nonconscnsus binding sites arc abo described [38] . Given their nature as transcription factors, aH Gli proteins also possess activation domains within their C-renninal region that imeracc with other transcriptional accessory proteins needed for the duomarin remodeling involved in active transcription. Omsidc of this organizational similarity, however, there arc distinct differences 4 between the three homologs that provide the basis for separation of functions in the Gli-mediated transcription process. For one, the proteins encoded by Gli2 and 3 also possess repressor domains within their N-tcrminus that can preferentially attract corepressor protein complexes to the DNA-binding sires when the activation domain is proteolytically removed [39, 40] . It is the relative efficiency with which these two Gli forms are specifically protcolyzcd that distinguishes the inactive versus the active hedgehog signaling state. In the absence of activated Smo, Gli2 and 3 proteins traffic into primary cilium where they arc modified into repressor forms [IJI] . This process is initiated by a series of sequential phosphorylarions, initiated by protein kinase A and then followed by glycogen synthase kinase-3-~ and casein kinase I. Following phosphorylation, the Gli2/3 repressor forms arc generated by proteolysis that may be guided by site-directed ubiquitylation under the control of SCFpTRcr !42]. The Gli2/3 modification and proteolytic process also requires the presence of certain ciliary kincsin motor proteins to shepherd Glis through the primary cilium and to scaffold the modification complex during the process [27] . The Gli2/3 proteins are also distinguished by their differing contributions to the repressive or activated Gli state of a cell. Whereas native Gli2 is a more avid transcriptional activator rhan native Gli3, cleaved Gli3 is a stronger transcriptional repressor when compared with cleaved Gli2, so the intensity of the response to hedgehog signaling in a target cell also depends upon the relative expression levels of the two different proteins in that celL Gli proteins are also targeted for ubiquitylation by the SPOP ubiquidn ligase [43] but it is unclear whether protcasomal degradation under this clement is involved in the specific generation of repressor forms ratber than their generalized degradation along with Glili41J]. In summary, the presence of activated Smo within rhc primary cilium suppresses the generation of the Gli2/3 repressor forms so rhey accumulate within the primary cilium in this state.
They arc also much more likely to exit the cilium with an intact C-terminal domain that is able to enter the nucleus, bind to Gli response elements and capture the chromarin accessory proteins required for an active transcription complex.
Given the importance of hedgchog/Gli signaling for vertebrate development and canc<~rs, there is considerable interest in the targets of active Gli-mcdiated transcription. Here, it is somewhat ironic that the most well-recognized targets of active Gli transcription include Glil and rhe Ptch genes that are mechanistically involved in the signaling process !<IS]. 'l"hc nature of the Glil protein, which lacks a repressor form, and its short-lived character suggests that it functions mainly as a means for amplifying the output of the hedgehog signaling process once it is initiated. Indeed, this function is consistent with lack of an overt phenotype in Glil-knockout mice whereas Gli2-or Gli3-knockouts are more severely affected !46.47]. By contrast, Ptch uprcgulation by active hedgehog provides a means to eventually diminish the activity of the signaling process once initiated, so this action appears to be part of a negative ICcdhack loop controlling hedgehog activity in any given target cell. Other genes reported to be hedgehog targets include hedgehog-interacting protein (HIP), whose gene product also feeds back to diminish local signaling activity; cell cycle regulators, including N-myc, eyelin 01 and 02, wbich may partially explain hedgehog effects on
The hedgehog/Gii signaling paradigm in prostate cancer cell growth; effectors of other developmental signaling pathways including Wnt and Notch ligands and other gene products (bd~2, FOX transcription factors, bone morphogenetic proteins and follistatin) (TAm l) that arc probably associated with differentiated stares. In summary, rhe spectrum of known hedgehog target genes reveals the autorcgulating nature of the signaling pathway and explains its obvious involvement in developmental organization of tissues, cell growth and differentiation.
The complex and unigue characteristics of the basic hedgehog signaling process, described in the previous section, allows for irs regulation at many alternative steps. These include imerfer~ ence with hedgehog ligand processing, release or receptor binding by effectors of sterol biosymhesis (32) or direct interference with mature ligand function by the presence of the HIP pro rein that binds to ligands and prevents their interaction with receptors [48] . For the target cell, hedgehog signaling can be facilitated by the presence of heparin proteoglycans and lower affinity hedgehog coreceptor proteins that include CDON and BOC [49) . Further downstream, integration of vertebrate hedgehog signaling into the primary cilium means that signal processing reguires the activities of numerous ciliar transport proteins to shuttle Cli proteins into and om of the cilium [lil,SO,Sl]. Genetic ablation of individual ciliar transport proteins in mice confers phenotypes that arc reiterative of mutations in the primary hedgehog regulatory genes. End~ stage Gli transcriptional activity is also affected by acetylation or sumoylation of the Gli proteins [52.53] . Finally, Cli nanscrip~ tiona! function is tempered by the presence of the multifunctional SuFu protein that can bind and sequester Gli active fimns in the cytoplasm or attract transcriptional corcpressors ro activator Gli complexes already bound to chromatin [54.55[. The multiplicity of alternative regulatory sites along the hedgehog signaling cascade provides copious opponunities for signal facilitation or inrcrfer~ cncc and it complicates attempts to understand the reason that hedgehog signaling abnormalities strongly underlie certain types of developmental defects or malignancies but not others.
Another notable aspect of hedgehog signaling is its remark~ ably sensitivity w small~molecule manipulation. This is mainly attributable to the unigue nature of the Smo molecule, whose activity is strongly influenced by its association with sterols or other low-molecular-weight compounds. Sterol~ like compounds, such as SAG [35) or purmorphomine [56] , promote the activated Smo state and these molecules provide an alternative means of antagonizing hedgehog for experimental purposes. By contrast, sterols modeled after the phyto~derivcd jervcratrum alkaloid, cyclopamine, strongly inhibit Smo activation and these drugs are frcgucndy used experimentally to antagonize hedgehog signaling [57) . The evidence that hyperactive hedgehog signaling plays a role in human cancers has been a tremendous impetus for the discovery of novel compounds that might be used for the purpose of therapeutics and these effOrts have resulted in the identification of numerous other !ow~molccular~weight compounds that can antagonize hedgehog or hlock Gli action. Since many of these newer compounds arc being considered for clinical utilization in oncology, we will assess the spectrum of potential hedgchog/Gii targeting agents in a later section of this article.
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Hedgehog in prostate development
Hedgehog's importance as a developmental morphogen for vcr~ tebrates is established by the striking developmental anomalies that arc associated with abrogation of pathway activity. Loss of Shh, Gli2 or Cli3 function in mutant or knockout mice can be embryonically lethal or result in the death of the neonate shortly after birth associated with developmental defects that include holoprocncephaly/cyclopism [58) , spinal cord anomalies and other neuronal deficits (59] , defects in the formation of the axial skeleton and limbs [60) , underdeveloped lungs, and anorectal mal forma~ tions that include persistent cloaca [6!) , depending on the sever~ ity of the pathway ablation. for males, sexual accessory tissue development is also affected by hedgehog deficiencies and this effect includes hypodevclopmcnt of the prostate gland.
The prostate gland is derived from the embryonic urogenital sinus (UGS) and Shh is expressed in rodent and human UGS and in the buds and ducts that outgrow from it during the process of prostate organogenesis and maturation [62] . Embryonic male mice that lack functional Shh as a consequence of homozygous mutation fail to show the early inductive budding from the UGS that initiates prostate formation [63.61i] . However, it is remarkable that inductive budding can be restored simply by supplementing testosterone to the female mouse (in m'vo} or to isolated mumnt male UGS rissucs (in vitro) [63] . These observations arc highly con~ sistent with a requirement of hedgehog for embryonic testicular steroidogenesis and feral androgcnization that guides the indue~ tivc phase of male sexual accessory tissue development [65] and they arc inconsistent with the idea that any prostate~autonomous hedgehog activity is reguired for initial organogenesis. Despite the evidence that prostate~autonomous Shh is unnecessary for UGS inductive budding, later embryonic ductal branching and neonatal maturation of the rodent prostate gland is markedly hampered by the lack of Shh, even when supplemental testa~ stcronc is provided. Thus, the secondary budding and ductal extension associated with late embryonic and neonatal prostate development is dependent upon prostate-autonomous hedgehog signaling. This developmental situation may be analogous to the regrowth of the regressed prostate in chronically castrated adult rodents that occurs subsequent to testosterone replenishment. Here, cyclopamine treatment was shown to block the androgenstimulated regrowth of the regressed adult mouse prostate associ~ a ted with tcscostcrone replacement and this outcome suggests that testosterone replacemem induces hedgehog expression needed for prostate ductal expansion in adults {66).
With regards to the nature of the hedgehog signaling process in the developing prostate, in situ hybridization and immuno~ histochemical analyses of embryonic or neonatal mouse and rat tissues tends to localize expression of Shh to the epithelium of the rodent UGS and to the growing tips of the prostate epithelial huds as they invade imo the surrounding mesodermally derived mesenchyme [67·-70) . By contrast, Ptch and Clil (the surrogate Gli target gene) were found co be mainly expressed by UGS mcscn~ chyme or stromal cells adjacent to buds of the developing prostate gland that also stain positive for smooth muscle actin. The strik~ ingjuxtaposition ofligand expression restricted to the developing Chen, Carkner & Buftyan prostate epithelium with receptor and target gene expression that is mainly found in rhc adjacent mesenchyme shows that hedgehog encompasses a typical paracrinc signaling process in the devel~ oping prostate that is characteristic of the hedgehog signaling paradigm in other types of developing tissues. There are, however, some reports that also find reduced expression ofPtchl and Glil in the epithelium at bud tips !67] and these findings raise questions that extend to human prostate cancer tissue studies as to whether there may be some autocrine-like hedgehog activity in prostate epithelial cells that manifests exclusively under conditions of rapid growth.
Hedgehog & human cancers
Genetically manipulated mouse models have established an oncogenic role for hedgehog signaling in certain tissues that is remarkably predictive of the occurrence of proven hedgehog-driven tumors in humans. Mice with haploinsufficicny of Prchl [71.72) , or those with haploinsufficiency ofSuFu when combined with p53 haploinsufficicncy [73) , develop a common spectrum of cutaneous, brain and cartilaginous tumors that corresponds to the specific types of gene anomalies found in basal cell (skin) carcinoma (BCC), medulloblastomas or rhabdomyosarcomas in humans [74) . These types of tumors often have reduced Ptch l expression associated with loss of heterozygosity at 9q22 (the Ptchl locus), which may or may not be associated with a mutation in the remaining Ptch allele {75]. Likewise, inactivating mutations in Ptch or SuFu underlie rhc Godin syndrome that predisposes to the development ofBCC and/or medulloblastoma [76, 77) . Conversely, mutations in the Smo gene that confer gain-offunction to the encoded protein arc also found in human BCCs and, rarely, in medulloblastomas [7&), but exogenous targeted expression of a mucanc human Smo gene from BCC in transgenic mice similarly induces cutaneous carcinomas, medulloblastomas and rhabdomyosarcomas. Collectively, the reiteration of tumor development in mice by the same genetic aberrations that arc found in human tumors of the same class validates the oncogenic nature of unrestricted hcdgchog/Gli signaling in this limited subset of tissues. Although these types of genetic lesions confer the appearance of'autocrinelike' auronomous hedgehog signaling activity in the tumor cell, the abnormal activity is indcpcndcm of the presence of hedgehog ligands in the rumor microenvironment.
Despite the lack of prevailing evidence for the occurrence of genetic lesions of the rype previously described in mosr other types of solid human tumors, considerable interest remains in the porcmial roles of hedgehog or Gli, especially for lung, breast, pancreas, colon and prostate carcinoma [12.13.66,79.80 ). As will be discussed for prostate cancer, rhe evidence for association usually encompasses findings of high expression of ligand and/or hedgehog target genes in tumor cells or findings that hedgehog/ Gli inhibition, usually by cyclopaminc or by Gli expression knockdown, suppresses cell growth in vitro or in vivo as tumor xcnografts in mice. The outcomes of these experiments arc often used to support rhe idea that some form autocrinc-likc hedgehog signaling is constitutively active in these other types of solid tumor cells. Unfortunately, much less effort is made to establish whether,
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indeed, any or all of these rumors demonstrate any actual autonomous hedgehog signaling activity, and experimental evidence more strongly implicates that these rumor systems arc more inAucnccd through paracrinc hedgehog !81], much like in the tissues from which these rumors develop. The situation for rumors other than BCC, medulloblastoma or rhabdomyosarcoma is especially complicated by observations that Gli expression can be regulated independently of hedgehog signaling. TGF-P-, P-catcnin-and hyperactive RAS/RAF/MEK/ERK-mediated signaling uprcgulatcs Gli expression/activity in tumor cells independent of the presence of hedgehog ligand [70, 82, 83) and hyperactivity of these alternate cell signaling pathways is known to occur in many different types of cancer. Given the existence of alrernativc pathways to Gli expression, one should certainly consider whether simple overcxprcssion of Gli, when combined with post-translational processing deficits that fail to generate Gli repressor forms, would be sufficient to explain Gli involvement in them without invoking further upstream hedgehog activities. This is a paradox that we will explore in our focus on prostate cancer.
Finally, the requirement for the primary cilium to process canonical hedgehog signaling in normal cells raises other questions regarding the existence of active hedgehog signaling in cancers that may lack hedgehog-activating mutations since primary cilium arc mainly formed on growth-arrested cells whereas cancer cells, especially in culture, usually lack these organelles [84] . The apparent absence of primary cilium in dividing cancer cells then raises critical questions as to how Smo might transition w the active form in cancer cells without activating mutations or evidence of other hedgehog signaling anomalies, and rhis is an area of research in which we hope to have advances in the coming years.
For those tumor systems that are commonly associated with hyperactive Smo function (due to loss of Ptch function or Smo mutations), rhcrc is good reason w consider the testing and usc ofSmo-targeting agents as anticancer therapeutics. Whereas there was some initial interest in the usc of cydopaminc in clinical practice, this agent has critical attributes that make it unfavorable for this purpose and these include its poor availability through nonvenous routes, as well as concerns that it has off-target effects, especially at higher doses [85] . Nonetheless, the remarkable sensitivity of Smo to small-molecule inhibition has encouraged discovery efforts to identify agents that act in a similar way to cycloparninc (by inhibiting Smo activation) with a more favorable clinical profiles. [90) , is of this class. Funhcr down the pathway, the knowledge that Gli acdviry may be an important factor in tumor biology, independent of hedgehog signaling, has also driven dis~ covcry cffons to identify drugs that can block this activity, and the Gli antagonists (GANTs; ~58 and -61} [91] , and, more rcccnrly, the HPI class of drugs (92] that interfere with Gli trafficking and transcription, may have clinical applicability. Finally, the actions of arsenic trioxide, which is being tested as a solid tumor therapeutic [93] , may also include the inactivation of Gli function in cancer cells (94, 95) so this drug may provide an alternative option for hedgehog targeting in cancers.
Overview of hedgehog/Gii in prostate cancer
The involvement of hedgehog signaling in prostate development forms a foundation for considering whether hedgehog/Gli might have some role in prostate malignancy. This concept received substantial impetus from two early reports of cyclopaminc-or Shh antihody-mediated suppression of prostate cancer cell growth in 11itro and in vivo [66, 96] , and the outcomes of these experimental studies were viewed as evidence for an active aurocrinc-like hedgehog signaling process in these cell lines. This conclusion should now be reconsidered, especially in light of the concerns discussed previously. A review of relevant literature on this topic with these new perspectives shows remarkable weaknesses in the argument that autocrine hedgehog has an important role in the develop~ ment of prostate cancer. For one, the genetically altered mouse models rhar were so useful for establishing a relationship herwccn abnormally hyperactive hedgehog signaling and the development of skin and brain malignancies have not shown any evidence that such aberrations lead to the devdopmcm of prostate neoplasia or malignancy. lc is especially notable that even mice with a pnmarc (epithelial cell)-specific knock-in of gain-of-function mmated Smo gene that is oncogenic when expressed in skin, brain or cartilage, demonstrated no evidence for any type of prostatic pathology [97] . In fact, at this time, the only report of an animal (mouse) model that develops prostate cancer from a hedgehog manipulation involves the direct introduction of a constitutive Shh expression vector into mouse prostate by tissue clcctropora~ tion [98] . These adulc mice uniformly developed prostate intraepithclial neoplasia that rapidly progressed to metascatic prostate adenocarcinoma over time. Unfortunately, varied outcomes from the numerous published efforts that describe and quantify expression of hedgehog-related genes in prostate rumors chaltcngc efforts to provide consensus on this issue. There arc general concerns that the so-called 'normal' regions of human prostate specimens that arc available for study might be affected by the common prostate benign disease states due might also invoke abnormal hedgehog responses [lOO] and this raises questions regarding the establishment of normal prostate basal expression levels for any of these genes. Approaches that assess RNA levels by in situ hybridiz<ltion arc complicated by the uneven cellular architecture of a prostate tumor (in which the cellularity of the stroma can appear sparse compared with the adjacent epithelium) and this might account for the conflicting findings of Glil RNAs localized ro hcnign and malignant prostate epithelium in one study [%] versus sdecdve expression in the stroma around tumors in another [IOO] . Likewise, quantitative reversc-transcriptasc PCR approaches that involve bulk extraction from tumor tissues are complicated by the comixrmcs of tumor and benign stromal cells in the specimens that complicate ana~ lysis, so it is difficult to comment on observations based on this approach. In situ immunohistochemical approaches using antibodies against hedgehog-related proteins offer the potential for higher detection specificity, with appropriately validated antibodies, bur this approach suffers from a diminished ahility to quantify outcomes.
With these considerations, the observations of Azoulay ct a/., who evaluated hedgehog ligand expressions in a cohort of 231 different prostate tumors, some of which were obtained from patients treated with hormone therapies, were remarkable [101] . They described a significant correlation between high(cr) expression ofShh in malignant epithelium with tumor grade or metas- (100] . This indicates that the higher expression ofShh foun~l in prostate tumors of higher grade has the potential to impact on prostate tumor growth rates. The fact that similar rumor growth acceleration can also be achieved by comixing unmodified LNCaP cells with UGS mesenchymal cells lacking Gli3 repressor ((;li3· '·) {103] certainly shows that signaling action through the paracrine pathway, at least has the potential to significantly concribute to the hedgehog-mediated rumor growth acceleration effect. Finally, observations that the trcatmenr of mice with Sbh-targeting antibodies, cyclopamine, Gli2-ta.rgcting antisense oligotides [102] or Gli-blocking drugs of the GANT class significantly inhibit the growth of prostate tumor cell xenografts (CWR22rvl or PC3 cells) identifies the potential for use of hedgehog-/Gli-suppressive therapeutics fOr prostate cancer treatment, although, to date, no actual clinical trials using hedgehog-blocking approaches for prostate cancer patients have been reponed.
Evaluation of prostate cancer cell lines in a culture sening provides a means of testing for the presence of any autocrine-like hedgehog signaling activities in the cells and whether activation or interference at various sites of the signaling pathway affects hedgehog target genes or cell growth outside the influence of a paracrine signaling environment. For the mo.~t commonly utilized human prostate cancer cell lines (LNCaP and derivatives, DUI45, PC3 or CWR22rvl) grown in culture, Shh, Glil/2 and other key hedgehog target genes (Ptchl, G/;J and HIP) arc, in general, reported to be expressed in most, although there is wide variability in individual levels among the differem lines. The most comprehensive survey for basal expression of hedgehog effector genes (mRNAs) in the common prostate cancer cell lines was 8 published by Zhang et ttl. (lo4) and this survey showed no overt concordance between the expression of hedgehog ligands (Shh or Ihh) and the basal expression of hedgehog surrogate targets (Glil and Ptchl), except for HIP; no concordance in the expression of the different hedgehog target genes in any of the lines; and, finally, no concordance between the expression of any of the Gli RNAs with Ptch or HIP expression. Likewise, the common prostate cancer cell lines were shown to he refractory to treatment with recombinant Shh protein or to adenoviral transduction of a mutated Smo gene !104] . Collectively, these findings do not lend support to the presence of a basally active or even an accessible endogenous hedgehog signaling process in any of rhe cell lines evaluated based upon the idea that the activity of the pathway is solely indicated by expression levels of known Gli target genes. Conceptually, the lack of evidence for intermediate hedgehog signaling activity in prostate cancer cell lines based upon these considerations then challenges the idea that cyclopamine treatment, which invariably affects the growth of these cells in vitro, is funcdonally targeting an active hedgehog signaling process guided by Smo activation. Here again, the failure of cyclopamine to suppress expression of hedgehog target genes (Ptchl, G!il or hedgehog reporter) in the cultured prostate cancer cell lines [104, 105] provides additional support for the lack of intermediate signaling pathway activity in the cancer cell lines, as long as one can be reassured that pathway activity is exclusively reHected by the relative expression levels of Gli target genes. As we wiU discuss later, this may not always be the case, at least in prostate cancer cells that express the AR protein. Regardless of these concerns, there are prominent indications that Gli proteins, at least, play some role in the growth potential of prostate cancer cells. Suppression ofGlil or Gli2 expression using gene-specific si-/shRNAs or antisense oligotides significantly reduced their in vitro growth rate and invasiveness [l02,J06,107) and increased the propensity for apoptosis. The mechanism supporting the presence of active G!i in these cells remains uncertain.
Hedgehog/Gii & androgen cross~talk in prostate cancer
The androgen signaling pathway that is so central to prostate cancer is remarkably interactive with other cell-signaling pathways. These interactions often occur at the level of the AR protein where AR activity can be increased under stimulation of signal-activated protein kinases [108) or by interaction with other pathway-regulated transcription factors, as is exemplified by ~-carenin in the Wnt signaling pathway [109] . These signaling interactions are especially notable when they support promiscuous androgen signaling under low androgen conditions, as this allows for the possibility that the secondary signaling pathway is a druggable rarget for suppression of CRPC. Recently, we learned of a unique bi~directional interaction between androgen and hedgehog signaling in prostate cancer cells. The namre of tbis interaction is defined by the androgenic milieu of the prostate cancer cell and it appears to have the potemial to produce a more active paracrinc hedgehog microenvironment of a tumor in hormone-treated patients and, at the same time, promote promiscuous activity of the tumor cell AR that enables androgen-independent growth. J efincd by evidence that hedgehog liga nds are a ndrogen-repressed genes in p rostate cancer cells. Using rhe example of cultured p rostate ca ncer cell lines char express A R and are growth-responsive ro the presence of and rogens in their medium, expression of m RNA encoding hedgehogs was found to be markedly increased by a switch to androgendepleted medium [101, 110] . For LNCaP cells, and rogen deplcrion upregulared Shh by 30 ,000-fold, and the expression of Ihh and Dhh was also upregulared, although nor ro this exrenr. T his response was nor unique ro LNCaP; or her androgen-responsive prostate ca ncer cells demonstrated similar changes in hed gehog expression when created in this manner. Moreover, the changes in Shh mRNA were accompanied by similar increases in the expression and release Vee 51JM
GANT-61
of rhe mature Shh polypeptide with inracr p aracrine function, shown by rhe finding char rhe conditioned growrh medium from and rogen-deprived, bur nor androgen-supplemented, LNCa P cells was able ro elicit a hedgehog respon se from mouse fibro blasts [IIOJ . T he clinical relevance of these in vitro find ings is supported by the previously mentioned survey of hedgehog expression in human prostate rumors [IOIJ, which included a group of rumors obrainc:d from LNCaP cells were seeded onto plates overnight in RPMI-1640 medium containing 10% fetal bovine serum, then switched to an androgen·depleted medium as was previously described [IIOI containing dimethyl sulfoxide vehicle only (Vee) or GANT-58 or GANT-61 dissolved in dimethyl sulfoxide at the indicated concentrations and was incubated for an additional 72 h. RNAs were then extracted from these cells and were assessed by quantitative real-time PCR for the expression of KLK2 or KLK3 (prostate-specific antigen), as described, and the results are normalized to expression of GAPDH in the same samples. Each point indicates the results from triplicate cultures. GANT: Gli antagonist.
patients w ho had been aJjuvandy treated with hormone therapy prior ro su rgery. H ere, hormone rrearmenr essenrially doubled rhe percentage of tumors fou nd ro express Shh or Dhh in malignant epithelium compared with unrreared rumors. In addition ro irs effect on hedgehog expression, androgen deprivation was also shown to sign ificantly increase the expression of G li 2 mRNA in LNCaP and other prostate cancer cell lines [110] . Considering rhe fac t that this actio n was also accompanied by upregul ared P tch I expression, one mig ht reasonably suppose that the coi ncidental increases in Sh h, G li 2 and Ptch expression represent the activities of an autocrine hedgehog cascad e initiated by androgen deprivation. Indeed, since cyclopamine rrearmenr conferred a small bur significant decrease in Prch expression u nder chis condition [IIOJ, the outcome further supports t he idea rhar androgen d eprivation is associated w ith a reawakening of some au rocrine-like activity in prostate cancer cells. Arguing against this is the fact th at G li l mRNA expression was significa ntly decreased by this same condition and it is d iffi cult to explain the striking discordance in the response of these two foremost G li target genes ( Glil and Ptchl), unless one invokes di ffe rent regulawry mechanisms for each gene operating in rhe confi nes of rhc androgen-deprived cell. T his remains an unresolved issue, which is furth er complicated by the evidence rhat active hedgehog/G ii affects androgen signaling in prostate cancer cells.
www.expcrt· reviews.com T he notion char heJgehog/G ii also affects and rogen signaling origi nated from observations of a dose-dependent effect of cyclopamine on the expression of and rogen-regulated genes [Ill) in LNCaP and other prostate ca ncer cells. Here, cyclopamine treatment was shown to specifica lly suppress expression of kallikreinrelated peptidase (KLK)2, KLK3 and PGC in androgen-deprived, but not androgen-supplemented, LNCaP cells, whereas it further induced expression ofShh, which represents an androgen-repressed gene. Cyclopamine had similar effects on expression of lucifcrasc reporters from anJrogen-dependent promoter elements in these cells. These effects were most pronounced in anJrogen-J epriveJ cells in which G li2 levels were eleva red. Whereas questions remain regarding cyclopamine's specificity and its mechanism of action in prostate cancer cell lines, a similar outcome was observed after knockdown of Smo expression using siRNA. T he fact chat this effect also involves elements of hedgehog (G ii activity) downstream ofSmo is indicated by the ability to suppress androgen-dependenr gene expression by specific reduction of Gi i2 expression or by treatments with the Gli inh ibitor drugs, C ANT-58 and -61 ( F1 cu• £ 2). H ere, it is notable chat the GANT drugs JiJ nor significantly affect expression of Ptchl. Finally, in rhe reverse paradigm, exogenous expression of Glil or G li2 in androgen-deprived prostate cancer cells not only increased the expression of androgen-dependent genes but also enabled t hese cells to grow in an androgen-deficient medium (111). Collcctivdy, the outcomes of these studies support the presence of a Smo-depcndcm signaling process, at least in androgen-deprived prostate cancer cells, which cross-talks with the androgen signaling pathway through Gli co affect androgenregulated gene expression. The involvement ofGli in the regulation of androgen-dependent genes suggests that the effect might be mediated by some form ofGli/AR interaction. Indeed, coimmunoprecipitation or two-hybrid analysis shows that Glil or Cli2 can dirccrly bind to the AR protein [111.112] . Based on these reports, the Gli proteins may have AR coactivation functions that contribute to androgen signaling, especially in the androgen-deprived stare.
Expert commentary
Since its discovery in 1980, we have learned a great deal regarding rhe mechanistic aspects of hedgehog signaling and its role in vertebrate development. In addition, we have come to accept its causative role in some forms of human cancer. The association of hedgehog signaling abnormalities with human tumors has spurred the development and resting of clinically useful drugs that target hedgehog/Gli, some of which arc already demonstrating efficacy as cancer therapeutics. However, our current knowledge regarding the role ofhedgehog/Gli signaling in prostate cancer remains relatively limited to the notion that the disease, once acquired, benefits from a paracrine hedgehog signaling influence that is driven by the production of hedgehog ligands by prostate rumor cells that act on adjacent benign (stromal) cells and feeds back to the tumor, stimulating tumor eel! growth and metasrasis. With regards to prostate tumor cells themselves, there is little evidence for the types of mutations or defects in hedgehog signaling genes that arc found in human skin and brain tumors, but this does not rule out the possibility that genetic anomalies in other hedgehog-regulating genes might be a factor in the disease. Furthermore, the indications that tumor Gli activity has a role in advanced/aggressive disease are relatively convincing, but there are many reasons to be skeptical as m whether the hyperactive Gli is a consequence of tumor ccll·autonomous hedgehog signaling through an active autocrine-like signaling process. Recent findings that the hormone therapies used to treat advanced prostate cancers have the potential to augment the paracrinc hedgehog signaling microenvironment of a prostate tumor, in conjunction with the findings that Gli proteins can interact with AR and confer androgcn~indcpcndcnr growth behavior on human prostate cancer cells, support the consideration of hedgehog-blocking drug therapy used in conjunction with hormone therapy for patients with advancedlrherapy-resistant disease. While drugs that target Smo are now clinically available and should be effective for suppression of hedgehog paracrine effects, the questions regarding the source of Gli activity in prostate cancers suggest that drugs that specifically target Gli may be more useful than Smo blockers alone as they might act on the paracrine hedgehog tumor microenvironment, as well as on tumor-autonomous Gli, allowing d-Tective disease control when used as an adjunct to hormone therapy.
Five~year view
The availability of clinically tested drugs that target hedgehog/ Gli suggests that clinical trials of hedgehog therapeutics for 10 prostate cancer arc likely to advance faster than the resolution of critical research issues that might guide the most effective application of these therapies. With this perspective, the field requires research advances in three focus areas to help resolve the hedgehog/Gli contribution to prostate cancer. The first involves further exploration of the hedgehog paracrine effect in prostate cancer. Here, the knowledge that hedgehog expression is induced by inflammation, as is common in the prostate, suggests that hyperactive paracrine hedgehog could explain the link between prosrate inflammation and prostate carcinogenesis and idcmif'y a role for hedgehog in prostate cancer etiology. Development of this concept should encompass surveys of human prostate tissues to correlate the presence of prostate inflammation with hedgehog expression in adjacent epithelium and involve attempts to create a mouse model of prostate cancer by conditional targeted ovcrexpression of Shh in the adult prostate epithelium. Further work is needed to identify the paracrine hedgehog-induced substances that arc produced by hedgehog-stimulated rumor support cells that induce prostate tumor growth. The second area of focus involves addressing the source of Gli hyperactivity in prostate cancer cdb: and defining the extent to which increased tumor-autonomous Gli activity is associated with progression to aggressive (metastatic) disease. We have described the consideradons leading many to questions about whether intermediary hedgehog signaling is even possible in prostate cancer cells and the evidence that Gli expression is not solely dependent upon an active hedgehog signaling process in prostate or other solid tumors. Can we then attribute Gli overexpression in prostate cancer to some specific alternate signaling process that increases with disease progression? The third area of research involves expanding our understanding of the cross-talk between hedge~ hog/Gii and its consequences for androgen signaling in prostate cancer cells. Research in this area should auempt to dissect the interaction sites of Gli with AR and define the extent to which the alternate Gli forms can coactivate or corepress AR transcription. More work is needed to resolve the question of the extent to which Gli is hijacked by the AR in prostate cancer cells and whether Gli activity is best measured in these cells by expression of androgen-regulated, rather than Gli-regulated, genes. Finally, the evidence that reduction in Smo expression in prostate cancer cells affects the expression of androgen-regulated genes also suggests the need to better understand Smo function in the context of the prostate cancer cell. 
